secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0001628280-23-022597
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics appoints Leonard Reyno, M.D. as Chief Medical Officer effective July 10, 2023
--------------------------------------------------------------------------------

- Dr. Reyno receives $550K base salary, $200K sign-on bonus, and up to 40% performance bonus.
- Inducement option for 276,000 shares (25% vests year 1, rest quarterly over three years) plus 61,300 RSUs vesting over four years.
- Reyno brings ~30 years of oncology clinical experience; previously led Padcev early development, Herceptin and Taxotere FDA approvals.
- Stockholders elected three Class III directors, approved executive compensation, ratified KPMG as auditor, and approved officer liability limitation charter amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023022597/0001628280-23-022597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023022597/cccc-20230620.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-022597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer